nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB11—Ethinyl Estradiol—osteoporosis	0.108	0.243	CbGbCtD
Ponatinib—ABCG2—Conjugated Estrogens—osteoporosis	0.0378	0.0847	CbGbCtD
Ponatinib—ABCG2—Estradiol—osteoporosis	0.0332	0.0743	CbGbCtD
Ponatinib—CYP2C8—Raloxifene—osteoporosis	0.0284	0.0636	CbGbCtD
Ponatinib—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0274	0.0614	CbGbCtD
Ponatinib—FGFR3—epiphyseal plate—osteoporosis	0.0272	0.343	CbGeAlD
Ponatinib—CYP2C8—Cholecalciferol—osteoporosis	0.0219	0.0491	CbGbCtD
Ponatinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.0186	0.0416	CbGbCtD
Ponatinib—CYP3A5—Estradiol—osteoporosis	0.0184	0.0412	CbGbCtD
Ponatinib—CYP2C8—Estradiol—osteoporosis	0.0177	0.0396	CbGbCtD
Ponatinib—CYP3A4—Estropipate—osteoporosis	0.0173	0.0387	CbGbCtD
Ponatinib—CYP3A4—Calcitriol—osteoporosis	0.0173	0.0387	CbGbCtD
Ponatinib—CYP2D6—Cholecalciferol—osteoporosis	0.014	0.0313	CbGbCtD
Ponatinib—CYP3A4—Ergocalciferol—osteoporosis	0.0138	0.0309	CbGbCtD
Ponatinib—ABCB1—Conjugated Estrogens—osteoporosis	0.0136	0.0305	CbGbCtD
Ponatinib—ABCB1—Estradiol—osteoporosis	0.012	0.0268	CbGbCtD
Ponatinib—CYP3A4—Raloxifene—osteoporosis	0.0115	0.0258	CbGbCtD
Ponatinib—FGFR3—skull—osteoporosis	0.0114	0.144	CbGeAlD
Ponatinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0111	0.0249	CbGbCtD
Ponatinib—CYP3A4—Cholecalciferol—osteoporosis	0.0089	0.0199	CbGbCtD
Ponatinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00817	0.0183	CbGbCtD
Ponatinib—SRC—periosteum—osteoporosis	0.00772	0.0974	CbGeAlD
Ponatinib—RET—parathyroid gland—osteoporosis	0.00765	0.0966	CbGeAlD
Ponatinib—FGFR2—skull—osteoporosis	0.00744	0.094	CbGeAlD
Ponatinib—CYP3A4—Estradiol—osteoporosis	0.00717	0.0161	CbGbCtD
Ponatinib—Nilotinib—CA2—osteoporosis	0.00212	0.545	CrCbGaD
Ponatinib—Imatinib—CA2—osteoporosis	0.00177	0.455	CrCbGaD
Ponatinib—BCR—uterus—osteoporosis	0.00164	0.0207	CbGeAlD
Ponatinib—FGFR2—Estradiol—Estropipate—osteoporosis	0.00157	0.368	CbGdCrCtD
Ponatinib—FGFR1—uterus—osteoporosis	0.00146	0.0184	CbGeAlD
Ponatinib—BCR—bone marrow—osteoporosis	0.00139	0.0175	CbGeAlD
Ponatinib—FLT3—bone marrow—osteoporosis	0.00138	0.0174	CbGeAlD
Ponatinib—LCK—uterus—osteoporosis	0.0013	0.0165	CbGeAlD
Ponatinib—FGFR2—uterus—osteoporosis	0.00124	0.0156	CbGeAlD
Ponatinib—FGFR2—Estradiol—Conjugated Estrogens—osteoporosis	0.00119	0.279	CbGdCrCtD
Ponatinib—TEK—uterus—osteoporosis	0.00119	0.015	CbGeAlD
Ponatinib—LCK—bone marrow—osteoporosis	0.00111	0.014	CbGeAlD
Ponatinib—PDGFRA—uterus—osteoporosis	0.00108	0.0136	CbGeAlD
Ponatinib—FGFR2—Estradiol—Ethinyl Estradiol—osteoporosis	0.000998	0.234	CbGdCrCtD
Ponatinib—KDR—uterus—osteoporosis	0.000971	0.0123	CbGeAlD
Ponatinib—KIT—uterus—osteoporosis	0.00086	0.0109	CbGeAlD
Ponatinib—KDR—bone marrow—osteoporosis	0.000824	0.0104	CbGeAlD
Ponatinib—ABL1—uterus—osteoporosis	0.000749	0.00945	CbGeAlD
Ponatinib—KIT—bone marrow—osteoporosis	0.00073	0.00922	CbGeAlD
Ponatinib—ABL1—bone marrow—osteoporosis	0.000636	0.00802	CbGeAlD
Ponatinib—ABL1—Levorphanol—Estradiol—osteoporosis	0.000509	0.119	CbGdCrCtD
Ponatinib—ABCG2—uterus—osteoporosis	0.000472	0.00596	CbGeAlD
Ponatinib—ABCG2—bone marrow—osteoporosis	0.000401	0.00506	CbGeAlD
Ponatinib—ABCB1—uterus—osteoporosis	0.000233	0.00294	CbGeAlD
Ponatinib—ABCB1—bone marrow—osteoporosis	0.000198	0.00249	CbGeAlD
Ponatinib—Body temperature increased—Estropipate—osteoporosis	0.000178	0.000728	CcSEcCtD
Ponatinib—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000178	0.000725	CcSEcCtD
Ponatinib—Infection—Risedronate—osteoporosis	0.000177	0.000723	CcSEcCtD
Ponatinib—Hepatobiliary disease—Estradiol—osteoporosis	0.000177	0.000722	CcSEcCtD
Ponatinib—Gastrointestinal pain—Ibandronate—osteoporosis	0.000177	0.000722	CcSEcCtD
Ponatinib—Arthralgia—Pamidronate—osteoporosis	0.000177	0.000722	CcSEcCtD
Ponatinib—Myalgia—Pamidronate—osteoporosis	0.000177	0.000722	CcSEcCtD
Ponatinib—Back pain—Conjugated Estrogens—osteoporosis	0.000177	0.000721	CcSEcCtD
Ponatinib—Epistaxis—Estradiol—osteoporosis	0.000176	0.00072	CcSEcCtD
Ponatinib—Abdominal pain—Alendronate—osteoporosis	0.000176	0.000717	CcSEcCtD
Ponatinib—Body temperature increased—Alendronate—osteoporosis	0.000176	0.000717	CcSEcCtD
Ponatinib—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000176	0.000717	CcSEcCtD
Ponatinib—Anaemia—Zoledronate—osteoporosis	0.000175	0.000716	CcSEcCtD
Ponatinib—Nervous system disorder—Risedronate—osteoporosis	0.000175	0.000714	CcSEcCtD
Ponatinib—Skin disorder—Risedronate—osteoporosis	0.000173	0.000707	CcSEcCtD
Ponatinib—Gastrointestinal pain—Calcitriol—osteoporosis	0.000173	0.000707	CcSEcCtD
Ponatinib—Abdominal pain—Raloxifene—osteoporosis	0.000173	0.000705	CcSEcCtD
Ponatinib—Body temperature increased—Raloxifene—osteoporosis	0.000173	0.000705	CcSEcCtD
Ponatinib—Vision blurred—Conjugated Estrogens—osteoporosis	0.000172	0.000703	CcSEcCtD
Ponatinib—Body temperature increased—Ibandronate—osteoporosis	0.000171	0.000698	CcSEcCtD
Ponatinib—Abdominal pain—Ibandronate—osteoporosis	0.000171	0.000698	CcSEcCtD
Ponatinib—Leukopenia—Zoledronate—osteoporosis	0.00017	0.000693	CcSEcCtD
Ponatinib—Oedema—Pamidronate—osteoporosis	0.00017	0.000692	CcSEcCtD
Ponatinib—Haemoglobin—Estradiol—osteoporosis	0.000169	0.000689	CcSEcCtD
Ponatinib—Infection—Pamidronate—osteoporosis	0.000168	0.000687	CcSEcCtD
Ponatinib—Haemorrhage—Estradiol—osteoporosis	0.000168	0.000685	CcSEcCtD
Ponatinib—Abdominal pain—Calcitriol—osteoporosis	0.000167	0.000683	CcSEcCtD
Ponatinib—Body temperature increased—Calcitriol—osteoporosis	0.000167	0.000683	CcSEcCtD
Ponatinib—Hypoaesthesia—Estradiol—osteoporosis	0.000167	0.000682	CcSEcCtD
Ponatinib—Nervous system disorder—Pamidronate—osteoporosis	0.000166	0.000678	CcSEcCtD
Ponatinib—Thrombocytopenia—Pamidronate—osteoporosis	0.000166	0.000677	CcSEcCtD
Ponatinib—Vomiting—Etidronic acid—osteoporosis	0.000166	0.000677	CcSEcCtD
Ponatinib—Cough—Zoledronate—osteoporosis	0.000166	0.000676	CcSEcCtD
Ponatinib—Oedema peripheral—Estradiol—osteoporosis	0.000165	0.000675	CcSEcCtD
Ponatinib—Connective tissue disorder—Estradiol—osteoporosis	0.000165	0.000673	CcSEcCtD
Ponatinib—Rash—Etidronic acid—osteoporosis	0.000164	0.000671	CcSEcCtD
Ponatinib—Dermatitis—Etidronic acid—osteoporosis	0.000164	0.00067	CcSEcCtD
Ponatinib—Hyperhidrosis—Pamidronate—osteoporosis	0.000164	0.000669	CcSEcCtD
Ponatinib—Hypertension—Zoledronate—osteoporosis	0.000164	0.000668	CcSEcCtD
Ponatinib—Headache—Etidronic acid—osteoporosis	0.000163	0.000667	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000162	0.000663	CcSEcCtD
Ponatinib—Asthenia—Estropipate—osteoporosis	0.000162	0.000661	CcSEcCtD
Ponatinib—Visual impairment—Estradiol—osteoporosis	0.000162	0.00066	CcSEcCtD
Ponatinib—Arthralgia—Zoledronate—osteoporosis	0.000162	0.000659	CcSEcCtD
Ponatinib—Myalgia—Zoledronate—osteoporosis	0.000162	0.000659	CcSEcCtD
Ponatinib—Insomnia—Risedronate—osteoporosis	0.000161	0.000658	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.00016	0.000655	CcSEcCtD
Ponatinib—Paraesthesia—Risedronate—osteoporosis	0.00016	0.000653	CcSEcCtD
Ponatinib—Pruritus—Estropipate—osteoporosis	0.00016	0.000651	CcSEcCtD
Ponatinib—Asthenia—Alendronate—osteoporosis	0.000159	0.000651	CcSEcCtD
Ponatinib—Cough—Conjugated Estrogens—osteoporosis	0.000159	0.00065	CcSEcCtD
Ponatinib—Dyspnoea—Risedronate—osteoporosis	0.000159	0.000649	CcSEcCtD
Ponatinib—Dry mouth—Zoledronate—osteoporosis	0.000158	0.000645	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000158	0.000644	CcSEcCtD
Ponatinib—Fatigue—Ethinyl Estradiol—osteoporosis	0.000158	0.000643	CcSEcCtD
Ponatinib—Pruritus—Alendronate—osteoporosis	0.000157	0.000642	CcSEcCtD
Ponatinib—Dyspepsia—Risedronate—osteoporosis	0.000157	0.00064	CcSEcCtD
Ponatinib—Eye disorder—Estradiol—osteoporosis	0.000157	0.00064	CcSEcCtD
Ponatinib—Constipation—Ethinyl Estradiol—osteoporosis	0.000156	0.000638	CcSEcCtD
Ponatinib—Cardiac disorder—Estradiol—osteoporosis	0.000156	0.000636	CcSEcCtD
Ponatinib—Flushing—Estradiol—osteoporosis	0.000156	0.000636	CcSEcCtD
Ponatinib—Arthralgia—Conjugated Estrogens—osteoporosis	0.000156	0.000635	CcSEcCtD
Ponatinib—Myalgia—Conjugated Estrogens—osteoporosis	0.000156	0.000635	CcSEcCtD
Ponatinib—Asthenia—Ibandronate—osteoporosis	0.000155	0.000633	CcSEcCtD
Ponatinib—Nausea—Etidronic acid—osteoporosis	0.000155	0.000632	CcSEcCtD
Ponatinib—Oedema—Zoledronate—osteoporosis	0.000155	0.000632	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000154	0.00063	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000154	0.00063	CcSEcCtD
Ponatinib—Diarrhoea—Estropipate—osteoporosis	0.000154	0.00063	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Risedronate—osteoporosis	0.000154	0.000628	CcSEcCtD
Ponatinib—Infection—Zoledronate—osteoporosis	0.000154	0.000628	CcSEcCtD
Ponatinib—Fatigue—Risedronate—osteoporosis	0.000154	0.000627	CcSEcCtD
Ponatinib—Insomnia—Pamidronate—osteoporosis	0.000153	0.000626	CcSEcCtD
Ponatinib—Pruritus—Ibandronate—osteoporosis	0.000153	0.000625	CcSEcCtD
Ponatinib—Constipation—Risedronate—osteoporosis	0.000153	0.000622	CcSEcCtD
Ponatinib—Pain—Risedronate—osteoporosis	0.000153	0.000622	CcSEcCtD
Ponatinib—Angiopathy—Estradiol—osteoporosis	0.000152	0.000622	CcSEcCtD
Ponatinib—Paraesthesia—Pamidronate—osteoporosis	0.000152	0.000621	CcSEcCtD
Ponatinib—Diarrhoea—Alendronate—osteoporosis	0.000152	0.00062	CcSEcCtD
Ponatinib—Asthenia—Calcitriol—osteoporosis	0.000152	0.00062	CcSEcCtD
Ponatinib—Nervous system disorder—Zoledronate—osteoporosis	0.000152	0.00062	CcSEcCtD
Ponatinib—Thrombocytopenia—Zoledronate—osteoporosis	0.000152	0.000619	CcSEcCtD
Ponatinib—Mediastinal disorder—Estradiol—osteoporosis	0.000151	0.000618	CcSEcCtD
Ponatinib—Dyspnoea—Pamidronate—osteoporosis	0.000151	0.000617	CcSEcCtD
Ponatinib—Chills—Estradiol—osteoporosis	0.000151	0.000615	CcSEcCtD
Ponatinib—Skin disorder—Zoledronate—osteoporosis	0.00015	0.000614	CcSEcCtD
Ponatinib—Pruritus—Calcitriol—osteoporosis	0.00015	0.000611	CcSEcCtD
Ponatinib—Hyperhidrosis—Zoledronate—osteoporosis	0.00015	0.000611	CcSEcCtD
Ponatinib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.00015	0.00061	CcSEcCtD
Ponatinib—Diarrhoea—Raloxifene—osteoporosis	0.00015	0.00061	CcSEcCtD
Ponatinib—Dyspepsia—Pamidronate—osteoporosis	0.000149	0.000609	CcSEcCtD
Ponatinib—Dizziness—Estropipate—osteoporosis	0.000149	0.000609	CcSEcCtD
Ponatinib—Oedema—Conjugated Estrogens—osteoporosis	0.000149	0.000608	CcSEcCtD
Ponatinib—Alopecia—Estradiol—osteoporosis	0.000148	0.000606	CcSEcCtD
Ponatinib—Infection—Conjugated Estrogens—osteoporosis	0.000148	0.000604	CcSEcCtD
Ponatinib—Diarrhoea—Ibandronate—osteoporosis	0.000148	0.000604	CcSEcCtD
Ponatinib—Decreased appetite—Pamidronate—osteoporosis	0.000147	0.000601	CcSEcCtD
Ponatinib—Mental disorder—Estradiol—osteoporosis	0.000147	0.0006	CcSEcCtD
Ponatinib—Dizziness—Alendronate—osteoporosis	0.000147	0.0006	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000146	0.000597	CcSEcCtD
Ponatinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000146	0.000597	CcSEcCtD
Ponatinib—Malnutrition—Estradiol—osteoporosis	0.000146	0.000597	CcSEcCtD
Ponatinib—Erythema—Estradiol—osteoporosis	0.000146	0.000597	CcSEcCtD
Ponatinib—Fatigue—Pamidronate—osteoporosis	0.000146	0.000596	CcSEcCtD
Ponatinib—Gastrointestinal pain—Risedronate—osteoporosis	0.000146	0.000595	CcSEcCtD
Ponatinib—Constipation—Pamidronate—osteoporosis	0.000145	0.000591	CcSEcCtD
Ponatinib—Pain—Pamidronate—osteoporosis	0.000145	0.000591	CcSEcCtD
Ponatinib—Diarrhoea—Calcitriol—osteoporosis	0.000145	0.000591	CcSEcCtD
Ponatinib—Skin disorder—Conjugated Estrogens—osteoporosis	0.000145	0.000591	CcSEcCtD
Ponatinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000145	0.00059	CcSEcCtD
Ponatinib—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000145	0.00059	CcSEcCtD
Ponatinib—Dizziness—Raloxifene—osteoporosis	0.000145	0.00059	CcSEcCtD
Ponatinib—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000144	0.000588	CcSEcCtD
Ponatinib—Vomiting—Estropipate—osteoporosis	0.000143	0.000585	CcSEcCtD
Ponatinib—Dizziness—Ibandronate—osteoporosis	0.000143	0.000584	CcSEcCtD
Ponatinib—Rash—Estropipate—osteoporosis	0.000142	0.000581	CcSEcCtD
Ponatinib—Dermatitis—Estropipate—osteoporosis	0.000142	0.00058	CcSEcCtD
Ponatinib—Back pain—Estradiol—osteoporosis	0.000141	0.000577	CcSEcCtD
Ponatinib—Headache—Estropipate—osteoporosis	0.000141	0.000577	CcSEcCtD
Ponatinib—Vomiting—Alendronate—osteoporosis	0.000141	0.000577	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000141	0.000576	CcSEcCtD
Ponatinib—Body temperature increased—Risedronate—osteoporosis	0.000141	0.000575	CcSEcCtD
Ponatinib—Abdominal pain—Risedronate—osteoporosis	0.000141	0.000575	CcSEcCtD
Ponatinib—Muscle spasms—Estradiol—osteoporosis	0.000141	0.000574	CcSEcCtD
Ponatinib—Rash—Alendronate—osteoporosis	0.00014	0.000572	CcSEcCtD
Ponatinib—Insomnia—Zoledronate—osteoporosis	0.00014	0.000571	CcSEcCtD
Ponatinib—Dermatitis—Alendronate—osteoporosis	0.00014	0.000571	CcSEcCtD
Ponatinib—Headache—Alendronate—osteoporosis	0.000139	0.000568	CcSEcCtD
Ponatinib—Paraesthesia—Zoledronate—osteoporosis	0.000139	0.000567	CcSEcCtD
Ponatinib—Vomiting—Raloxifene—osteoporosis	0.000139	0.000567	CcSEcCtD
Ponatinib—Gastrointestinal pain—Pamidronate—osteoporosis	0.000139	0.000566	CcSEcCtD
Ponatinib—Dyspnoea—Zoledronate—osteoporosis	0.000138	0.000563	CcSEcCtD
Ponatinib—Rash—Raloxifene—osteoporosis	0.000138	0.000562	CcSEcCtD
Ponatinib—Dermatitis—Raloxifene—osteoporosis	0.000138	0.000562	CcSEcCtD
Ponatinib—Vomiting—Ibandronate—osteoporosis	0.000138	0.000561	CcSEcCtD
Ponatinib—Headache—Raloxifene—osteoporosis	0.000137	0.000559	CcSEcCtD
Ponatinib—Rash—Ibandronate—osteoporosis	0.000136	0.000557	CcSEcCtD
Ponatinib—Dermatitis—Ibandronate—osteoporosis	0.000136	0.000556	CcSEcCtD
Ponatinib—Dyspepsia—Zoledronate—osteoporosis	0.000136	0.000556	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000136	0.000554	CcSEcCtD
Ponatinib—Headache—Ibandronate—osteoporosis	0.000136	0.000553	CcSEcCtD
Ponatinib—Insomnia—Conjugated Estrogens—osteoporosis	0.000135	0.00055	CcSEcCtD
Ponatinib—Vomiting—Calcitriol—osteoporosis	0.000135	0.00055	CcSEcCtD
Ponatinib—Decreased appetite—Zoledronate—osteoporosis	0.000135	0.000549	CcSEcCtD
Ponatinib—Nausea—Estropipate—osteoporosis	0.000134	0.000547	CcSEcCtD
Ponatinib—Body temperature increased—Pamidronate—osteoporosis	0.000134	0.000547	CcSEcCtD
Ponatinib—Abdominal pain—Pamidronate—osteoporosis	0.000134	0.000547	CcSEcCtD
Ponatinib—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000134	0.000546	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000134	0.000545	CcSEcCtD
Ponatinib—Rash—Calcitriol—osteoporosis	0.000134	0.000545	CcSEcCtD
Ponatinib—Fatigue—Zoledronate—osteoporosis	0.000134	0.000545	CcSEcCtD
Ponatinib—Dermatitis—Calcitriol—osteoporosis	0.000133	0.000544	CcSEcCtD
Ponatinib—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000133	0.000542	CcSEcCtD
Ponatinib—Headache—Calcitriol—osteoporosis	0.000133	0.000541	CcSEcCtD
Ponatinib—Constipation—Zoledronate—osteoporosis	0.000132	0.00054	CcSEcCtD
Ponatinib—Pain—Zoledronate—osteoporosis	0.000132	0.00054	CcSEcCtD
Ponatinib—Nausea—Alendronate—osteoporosis	0.000132	0.000539	CcSEcCtD
Ponatinib—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000131	0.000536	CcSEcCtD
Ponatinib—Asthenia—Ethinyl Estradiol—osteoporosis	0.000131	0.000535	CcSEcCtD
Ponatinib—Nausea—Raloxifene—osteoporosis	0.00013	0.00053	CcSEcCtD
Ponatinib—Decreased appetite—Conjugated Estrogens—osteoporosis	0.00013	0.000529	CcSEcCtD
Ponatinib—Pruritus—Ethinyl Estradiol—osteoporosis	0.000129	0.000528	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000129	0.000525	CcSEcCtD
Ponatinib—Fatigue—Conjugated Estrogens—osteoporosis	0.000129	0.000525	CcSEcCtD
Ponatinib—Nausea—Ibandronate—osteoporosis	0.000129	0.000524	CcSEcCtD
Ponatinib—Asthenia—Risedronate—osteoporosis	0.000128	0.000522	CcSEcCtD
Ponatinib—Cough—Estradiol—osteoporosis	0.000128	0.000521	CcSEcCtD
Ponatinib—Constipation—Conjugated Estrogens—osteoporosis	0.000128	0.00052	CcSEcCtD
Ponatinib—Pain—Conjugated Estrogens—osteoporosis	0.000128	0.00052	CcSEcCtD
Ponatinib—Gastrointestinal pain—Zoledronate—osteoporosis	0.000127	0.000517	CcSEcCtD
Ponatinib—Hypertension—Estradiol—osteoporosis	0.000126	0.000515	CcSEcCtD
Ponatinib—Pruritus—Risedronate—osteoporosis	0.000126	0.000515	CcSEcCtD
Ponatinib—Nausea—Calcitriol—osteoporosis	0.000126	0.000513	CcSEcCtD
Ponatinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000125	0.000511	CcSEcCtD
Ponatinib—Arthralgia—Estradiol—osteoporosis	0.000124	0.000508	CcSEcCtD
Ponatinib—Myalgia—Estradiol—osteoporosis	0.000124	0.000508	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000124	0.000504	CcSEcCtD
Ponatinib—Abdominal pain—Zoledronate—osteoporosis	0.000122	0.000499	CcSEcCtD
Ponatinib—Body temperature increased—Zoledronate—osteoporosis	0.000122	0.000499	CcSEcCtD
Ponatinib—Diarrhoea—Risedronate—osteoporosis	0.000122	0.000498	CcSEcCtD
Ponatinib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000122	0.000497	CcSEcCtD
Ponatinib—Dry mouth—Estradiol—osteoporosis	0.000122	0.000497	CcSEcCtD
Ponatinib—Asthenia—Pamidronate—osteoporosis	0.000122	0.000496	CcSEcCtD
Ponatinib—Dizziness—Ethinyl Estradiol—osteoporosis	0.000121	0.000493	CcSEcCtD
Ponatinib—Pruritus—Pamidronate—osteoporosis	0.00012	0.000489	CcSEcCtD
Ponatinib—Oedema—Estradiol—osteoporosis	0.000119	0.000487	CcSEcCtD
Ponatinib—Infection—Estradiol—osteoporosis	0.000119	0.000484	CcSEcCtD
Ponatinib—Dizziness—Risedronate—osteoporosis	0.000118	0.000481	CcSEcCtD
Ponatinib—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000118	0.000481	CcSEcCtD
Ponatinib—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000118	0.000481	CcSEcCtD
Ponatinib—Nervous system disorder—Estradiol—osteoporosis	0.000117	0.000477	CcSEcCtD
Ponatinib—Vomiting—Ethinyl Estradiol—osteoporosis	0.000116	0.000474	CcSEcCtD
Ponatinib—Diarrhoea—Pamidronate—osteoporosis	0.000116	0.000473	CcSEcCtD
Ponatinib—Skin disorder—Estradiol—osteoporosis	0.000116	0.000473	CcSEcCtD
Ponatinib—Hyperhidrosis—Estradiol—osteoporosis	0.000115	0.000471	CcSEcCtD
Ponatinib—Rash—Ethinyl Estradiol—osteoporosis	0.000115	0.000471	CcSEcCtD
Ponatinib—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000115	0.00047	CcSEcCtD
Ponatinib—Headache—Ethinyl Estradiol—osteoporosis	0.000115	0.000468	CcSEcCtD
Ponatinib—Vomiting—Risedronate—osteoporosis	0.000113	0.000463	CcSEcCtD
Ponatinib—Rash—Risedronate—osteoporosis	0.000112	0.000459	CcSEcCtD
Ponatinib—Dermatitis—Risedronate—osteoporosis	0.000112	0.000458	CcSEcCtD
Ponatinib—Dizziness—Pamidronate—osteoporosis	0.000112	0.000457	CcSEcCtD
Ponatinib—Headache—Risedronate—osteoporosis	0.000112	0.000456	CcSEcCtD
Ponatinib—Asthenia—Zoledronate—osteoporosis	0.000111	0.000453	CcSEcCtD
Ponatinib—Pruritus—Zoledronate—osteoporosis	0.00011	0.000447	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000109	0.000444	CcSEcCtD
Ponatinib—Nausea—Ethinyl Estradiol—osteoporosis	0.000109	0.000443	CcSEcCtD
Ponatinib—Insomnia—Estradiol—osteoporosis	0.000108	0.00044	CcSEcCtD
Ponatinib—Vomiting—Pamidronate—osteoporosis	0.000108	0.00044	CcSEcCtD
Ponatinib—Paraesthesia—Estradiol—osteoporosis	0.000107	0.000437	CcSEcCtD
Ponatinib—Asthenia—Conjugated Estrogens—osteoporosis	0.000107	0.000436	CcSEcCtD
Ponatinib—Rash—Pamidronate—osteoporosis	0.000107	0.000436	CcSEcCtD
Ponatinib—Dermatitis—Pamidronate—osteoporosis	0.000107	0.000436	CcSEcCtD
Ponatinib—Dyspnoea—Estradiol—osteoporosis	0.000106	0.000434	CcSEcCtD
Ponatinib—Headache—Pamidronate—osteoporosis	0.000106	0.000433	CcSEcCtD
Ponatinib—Diarrhoea—Zoledronate—osteoporosis	0.000106	0.000432	CcSEcCtD
Ponatinib—Nausea—Risedronate—osteoporosis	0.000106	0.000432	CcSEcCtD
Ponatinib—Pruritus—Conjugated Estrogens—osteoporosis	0.000105	0.00043	CcSEcCtD
Ponatinib—Dyspepsia—Estradiol—osteoporosis	0.000105	0.000429	CcSEcCtD
Ponatinib—Decreased appetite—Estradiol—osteoporosis	0.000104	0.000423	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Estradiol—osteoporosis	0.000103	0.00042	CcSEcCtD
Ponatinib—Fatigue—Estradiol—osteoporosis	0.000103	0.00042	CcSEcCtD
Ponatinib—Dizziness—Zoledronate—osteoporosis	0.000102	0.000418	CcSEcCtD
Ponatinib—Constipation—Estradiol—osteoporosis	0.000102	0.000416	CcSEcCtD
Ponatinib—Pain—Estradiol—osteoporosis	0.000102	0.000416	CcSEcCtD
Ponatinib—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000102	0.000416	CcSEcCtD
Ponatinib—Nausea—Pamidronate—osteoporosis	0.000101	0.000411	CcSEcCtD
Ponatinib—Dizziness—Conjugated Estrogens—osteoporosis	9.86e-05	0.000402	CcSEcCtD
Ponatinib—Vomiting—Zoledronate—osteoporosis	9.85e-05	0.000402	CcSEcCtD
Ponatinib—Rash—Zoledronate—osteoporosis	9.76e-05	0.000398	CcSEcCtD
Ponatinib—Gastrointestinal pain—Estradiol—osteoporosis	9.76e-05	0.000398	CcSEcCtD
Ponatinib—Dermatitis—Zoledronate—osteoporosis	9.76e-05	0.000398	CcSEcCtD
Ponatinib—Headache—Zoledronate—osteoporosis	9.7e-05	0.000396	CcSEcCtD
Ponatinib—Vomiting—Conjugated Estrogens—osteoporosis	9.48e-05	0.000387	CcSEcCtD
Ponatinib—Abdominal pain—Estradiol—osteoporosis	9.43e-05	0.000385	CcSEcCtD
Ponatinib—Body temperature increased—Estradiol—osteoporosis	9.43e-05	0.000385	CcSEcCtD
Ponatinib—Rash—Conjugated Estrogens—osteoporosis	9.4e-05	0.000384	CcSEcCtD
Ponatinib—Dermatitis—Conjugated Estrogens—osteoporosis	9.39e-05	0.000383	CcSEcCtD
Ponatinib—Headache—Conjugated Estrogens—osteoporosis	9.34e-05	0.000381	CcSEcCtD
Ponatinib—Nausea—Zoledronate—osteoporosis	9.2e-05	0.000375	CcSEcCtD
Ponatinib—Nausea—Conjugated Estrogens—osteoporosis	8.86e-05	0.000361	CcSEcCtD
Ponatinib—Asthenia—Estradiol—osteoporosis	8.56e-05	0.000349	CcSEcCtD
Ponatinib—Pruritus—Estradiol—osteoporosis	8.44e-05	0.000344	CcSEcCtD
Ponatinib—Diarrhoea—Estradiol—osteoporosis	8.17e-05	0.000333	CcSEcCtD
Ponatinib—Dizziness—Estradiol—osteoporosis	7.89e-05	0.000322	CcSEcCtD
Ponatinib—Vomiting—Estradiol—osteoporosis	7.59e-05	0.00031	CcSEcCtD
Ponatinib—Rash—Estradiol—osteoporosis	7.52e-05	0.000307	CcSEcCtD
Ponatinib—Dermatitis—Estradiol—osteoporosis	7.52e-05	0.000307	CcSEcCtD
Ponatinib—Headache—Estradiol—osteoporosis	7.48e-05	0.000305	CcSEcCtD
Ponatinib—Nausea—Estradiol—osteoporosis	7.09e-05	0.000289	CcSEcCtD
Ponatinib—SRC—Signaling Pathways—PTHLH—osteoporosis	8.12e-06	3.67e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BMP2—osteoporosis	8.12e-06	3.67e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CALCA—osteoporosis	8.07e-06	3.65e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GAPDH—osteoporosis	8.03e-06	3.63e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ADCY5—osteoporosis	7.96e-06	3.6e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—POMC—osteoporosis	7.96e-06	3.6e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGB—osteoporosis	7.94e-06	3.59e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ADCY5—osteoporosis	7.94e-06	3.59e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP27A1—osteoporosis	7.89e-06	3.57e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AGER—osteoporosis	7.89e-06	3.57e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ADCY5—osteoporosis	7.86e-06	3.56e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—RAP1A—osteoporosis	7.82e-06	3.54e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ATIC—osteoporosis	7.79e-06	3.53e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PNP—osteoporosis	7.79e-06	3.53e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6R—osteoporosis	7.77e-06	3.52e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IRS2—osteoporosis	7.77e-06	3.52e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6R—osteoporosis	7.76e-06	3.51e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6R—osteoporosis	7.74e-06	3.5e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SPP1—osteoporosis	7.7e-06	3.49e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SPP1—osteoporosis	7.68e-06	3.48e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ACP5—osteoporosis	7.68e-06	3.48e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	7.68e-06	3.47e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PSMA2—osteoporosis	7.67e-06	3.47e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PSMA5—osteoporosis	7.67e-06	3.47e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—IL6—osteoporosis	7.66e-06	3.47e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	7.66e-06	3.47e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IGF1—osteoporosis	7.65e-06	3.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—IL6—osteoporosis	7.65e-06	3.46e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IL6—osteoporosis	7.62e-06	3.45e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TPI1—osteoporosis	7.58e-06	3.43e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—IL6—osteoporosis	7.56e-06	3.42e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—MYC—osteoporosis	7.54e-06	3.41e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MTHFR—osteoporosis	7.54e-06	3.41e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—TGFB1—osteoporosis	7.52e-06	3.4e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IRS2—osteoporosis	7.47e-06	3.38e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—POMC—osteoporosis	7.4e-06	3.35e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IRS2—osteoporosis	7.34e-06	3.32e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KL—osteoporosis	7.33e-06	3.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—LEP—osteoporosis	7.31e-06	3.31e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ENO1—osteoporosis	7.3e-06	3.3e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ADCY5—osteoporosis	7.26e-06	3.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—IL6—osteoporosis	7.25e-06	3.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL1B—osteoporosis	7.21e-06	3.26e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PSMA5—osteoporosis	7.19e-06	3.25e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PSMA2—osteoporosis	7.19e-06	3.25e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TGFB1—osteoporosis	7.18e-06	3.25e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—LEP—osteoporosis	7.18e-06	3.25e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IRS2—osteoporosis	7.17e-06	3.25e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CALCA—osteoporosis	7.14e-06	3.23e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TPI1—osteoporosis	7.14e-06	3.23e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MYC—osteoporosis	7.14e-06	3.23e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—P4HB—osteoporosis	7.12e-06	3.22e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TGFB1—osteoporosis	7.12e-06	3.22e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—IL6—osteoporosis	7.12e-06	3.22e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL1B—osteoporosis	7.08e-06	3.21e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ADCY5—osteoporosis	7e-06	3.17e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GAPDH—osteoporosis	6.99e-06	3.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ESR1—osteoporosis	6.98e-06	3.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IRS2—osteoporosis	6.97e-06	3.15e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IRS2—osteoporosis	6.95e-06	3.14e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IRS2—osteoporosis	6.88e-06	3.11e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ESR1—osteoporosis	6.86e-06	3.1e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—IL6—osteoporosis	6.84e-06	3.1e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	6.82e-06	3.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—LEP—osteoporosis	6.82e-06	3.09e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—RAP1A—osteoporosis	6.81e-06	3.08e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—LEP—osteoporosis	6.8e-06	3.08e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IRS1—osteoporosis	6.78e-06	3.07e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SPP1—osteoporosis	6.78e-06	3.07e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—IL6—osteoporosis	6.76e-06	3.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—IL6—osteoporosis	6.74e-06	3.05e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—IL6—osteoporosis	6.73e-06	3.05e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL1B—osteoporosis	6.72e-06	3.04e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—P4HB—osteoporosis	6.71e-06	3.04e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1B—osteoporosis	6.7e-06	3.03e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—IL6—osteoporosis	6.7e-06	3.03e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MTHFR—osteoporosis	6.67e-06	3.02e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ADCY5—osteoporosis	6.65e-06	3.01e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—GPX1—osteoporosis	6.63e-06	3e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—OXCT1—osteoporosis	6.63e-06	3e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CA2—osteoporosis	6.63e-06	3e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GAPDH—osteoporosis	6.59e-06	2.98e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IRS1—osteoporosis	6.52e-06	2.95e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ESR1—osteoporosis	6.51e-06	2.95e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ESR1—osteoporosis	6.49e-06	2.94e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KL—osteoporosis	6.49e-06	2.94e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TGFB1—osteoporosis	6.48e-06	2.93e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MGLL—osteoporosis	6.46e-06	2.92e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—RAP1A—osteoporosis	6.42e-06	2.9e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IRS1—osteoporosis	6.41e-06	2.9e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6R—osteoporosis	6.37e-06	2.88e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TGFB1—osteoporosis	6.36e-06	2.88e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IRS2—osteoporosis	6.35e-06	2.87e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ENO1—osteoporosis	6.32e-06	2.86e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—POMC—osteoporosis	6.28e-06	2.84e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IRS1—osteoporosis	6.26e-06	2.83e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PSMA5—osteoporosis	6.23e-06	2.82e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PSMA2—osteoporosis	6.23e-06	2.82e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—POMC—osteoporosis	6.17e-06	2.79e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—osteoporosis	6.14e-06	2.78e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6R—osteoporosis	6.13e-06	2.77e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IRS2—osteoporosis	6.13e-06	2.77e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—MTHFR—osteoporosis	6.12e-06	2.77e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IRS1—osteoporosis	6.08e-06	2.75e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IRS1—osteoporosis	6.06e-06	2.75e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—osteoporosis	6.05e-06	2.74e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IGF1—osteoporosis	6.04e-06	2.74e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6R—osteoporosis	6.02e-06	2.72e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IRS1—osteoporosis	6e-06	2.72e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—LEP—osteoporosis	6e-06	2.71e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—osteoporosis	5.94e-06	2.69e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IGF1—osteoporosis	5.93e-06	2.69e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—osteoporosis	5.92e-06	2.68e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1B—osteoporosis	5.91e-06	2.68e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1B—osteoporosis	5.89e-06	2.66e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6R—osteoporosis	5.88e-06	2.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—POMC—osteoporosis	5.86e-06	2.65e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—POMC—osteoporosis	5.84e-06	2.64e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP19A1—osteoporosis	5.83e-06	2.64e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ADCY5—osteoporosis	5.74e-06	2.6e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ESR1—osteoporosis	5.73e-06	2.59e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6R—osteoporosis	5.71e-06	2.59e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6R—osteoporosis	5.7e-06	2.58e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—osteoporosis	5.67e-06	2.57e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6R—osteoporosis	5.64e-06	2.55e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IGF1—osteoporosis	5.63e-06	2.55e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IGF1—osteoporosis	5.62e-06	2.54e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SPP1—osteoporosis	5.55e-06	2.51e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IRS1—osteoporosis	5.54e-06	2.51e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ENO1—osteoporosis	5.5e-06	2.49e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—IDH2—osteoporosis	5.49e-06	2.48e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PSMA2—osteoporosis	5.42e-06	2.46e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PSMA5—osteoporosis	5.42e-06	2.46e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—osteoporosis	5.37e-06	2.43e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IRS1—osteoporosis	5.35e-06	2.42e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MYC—osteoporosis	5.28e-06	2.39e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TGFB1—osteoporosis	5.27e-06	2.38e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6R—osteoporosis	5.21e-06	2.36e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO1—osteoporosis	5.19e-06	2.35e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MYC—osteoporosis	5.19e-06	2.35e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—TGFB1—osteoporosis	5.17e-06	2.34e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	5.16e-06	2.34e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—POMC—osteoporosis	5.15e-06	2.33e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PSMA5—osteoporosis	5.11e-06	2.31e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PSMA2—osteoporosis	5.11e-06	2.31e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MYC—osteoporosis	5.09e-06	2.31e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ADCY5—osteoporosis	5.08e-06	2.3e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—TGFB1—osteoporosis	5.08e-06	2.3e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP19A1—osteoporosis	5.05e-06	2.29e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6R—osteoporosis	5.03e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IRS2—osteoporosis	5.02e-06	2.27e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ACP5—osteoporosis	5.02e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IGF1—osteoporosis	4.96e-06	2.24e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SPP1—osteoporosis	4.92e-06	2.23e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—LEP—osteoporosis	4.92e-06	2.22e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—POMC—osteoporosis	4.89e-06	2.21e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—osteoporosis	4.88e-06	2.21e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—osteoporosis	4.87e-06	2.21e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1B—osteoporosis	4.85e-06	2.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MYC—osteoporosis	4.83e-06	2.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—TGFB1—osteoporosis	4.82e-06	2.18e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MYC—osteoporosis	4.82e-06	2.18e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—TGFB1—osteoporosis	4.81e-06	2.18e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ADCY5—osteoporosis	4.77e-06	2.16e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GPX1—osteoporosis	4.75e-06	2.15e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ESR1—osteoporosis	4.69e-06	2.12e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TPI1—osteoporosis	4.67e-06	2.11e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—osteoporosis	4.6e-06	2.08e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TGFB1—osteoporosis	4.59e-06	2.08e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IRS2—osteoporosis	4.45e-06	2.01e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP19A1—osteoporosis	4.4e-06	1.99e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—P4HB—osteoporosis	4.39e-06	1.99e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IRS1—osteoporosis	4.38e-06	1.98e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—MTHFR—osteoporosis	4.38e-06	1.98e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—LEP—osteoporosis	4.35e-06	1.97e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—osteoporosis	4.31e-06	1.95e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GAPDH—osteoporosis	4.31e-06	1.95e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—osteoporosis	4.29e-06	1.94e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—POMC—osteoporosis	4.22e-06	1.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—osteoporosis	4.22e-06	1.91e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—RAP1A—osteoporosis	4.2e-06	1.9e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ESR1—osteoporosis	4.15e-06	1.88e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP19A1—osteoporosis	4.15e-06	1.88e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—osteoporosis	4.15e-06	1.88e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ADCY5—osteoporosis	4.13e-06	1.87e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6R—osteoporosis	4.12e-06	1.86e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—osteoporosis	4.11e-06	1.86e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IGF1—osteoporosis	4.06e-06	1.84e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—osteoporosis	3.97e-06	1.8e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—osteoporosis	3.94e-06	1.78e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—osteoporosis	3.93e-06	1.78e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—osteoporosis	3.9e-06	1.76e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IRS1—osteoporosis	3.88e-06	1.76e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—osteoporosis	3.83e-06	1.73e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—MTHFR—osteoporosis	3.8e-06	1.72e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—POMC—osteoporosis	3.74e-06	1.69e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6R—osteoporosis	3.65e-06	1.65e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—osteoporosis	3.63e-06	1.64e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—osteoporosis	3.63e-06	1.64e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—osteoporosis	3.62e-06	1.64e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—osteoporosis	3.62e-06	1.64e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ADCY5—osteoporosis	3.6e-06	1.63e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IGF1—osteoporosis	3.6e-06	1.63e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—osteoporosis	3.58e-06	1.62e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—osteoporosis	3.57e-06	1.61e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—osteoporosis	3.56e-06	1.61e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—osteoporosis	3.51e-06	1.59e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—osteoporosis	3.49e-06	1.58e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—osteoporosis	3.48e-06	1.57e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—osteoporosis	3.46e-06	1.57e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—osteoporosis	3.46e-06	1.56e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—osteoporosis	3.45e-06	1.56e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO1—osteoporosis	3.39e-06	1.54e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ADCY5—osteoporosis	3.39e-06	1.53e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—osteoporosis	3.38e-06	1.53e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—osteoporosis	3.38e-06	1.53e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—osteoporosis	3.38e-06	1.53e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—osteoporosis	3.38e-06	1.53e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—osteoporosis	3.37e-06	1.52e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSMA5—osteoporosis	3.34e-06	1.51e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSMA2—osteoporosis	3.34e-06	1.51e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—MTHFR—osteoporosis	3.31e-06	1.5e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—MTHFR—osteoporosis	3.12e-06	1.41e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—osteoporosis	3.09e-06	1.4e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—osteoporosis	3.08e-06	1.39e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—osteoporosis	3.04e-06	1.37e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—osteoporosis	2.98e-06	1.35e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—osteoporosis	2.97e-06	1.34e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—osteoporosis	2.84e-06	1.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—osteoporosis	2.73e-06	1.24e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	2.71e-06	1.23e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—osteoporosis	2.68e-06	1.21e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—osteoporosis	2.64e-06	1.2e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—osteoporosis	2.62e-06	1.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—osteoporosis	2.54e-06	1.15e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—osteoporosis	2.54e-06	1.15e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—osteoporosis	2.51e-06	1.14e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—osteoporosis	2.49e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—osteoporosis	2.44e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—osteoporosis	2.43e-06	1.1e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—osteoporosis	2.32e-06	1.05e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—osteoporosis	2.24e-06	1.01e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ADCY5—osteoporosis	2.22e-06	1e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—osteoporosis	2.21e-06	9.99e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—osteoporosis	2.16e-06	9.78e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—osteoporosis	2.16e-06	9.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—MTHFR—osteoporosis	2.04e-06	9.22e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—osteoporosis	1.83e-06	8.3e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—osteoporosis	1.63e-06	7.38e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—osteoporosis	1.62e-06	7.35e-06	CbGpPWpGaD
